Get the Stockscreener App
2.73
18.70%
0.43
After Hours:
2.74
0.01
+0.37%
Humacyte Inc stock is traded at $2.73, with a volume of 2.62M.
It is up +18.70% in the last 24 hours and up +23.53% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$2.30
Open:
$2.64
24h Volume:
2.62M
Relative Volume:
0.68
Market Cap:
$423.47M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-2.5514
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+14.23%
1M Performance:
+23.53%
6M Performance:
-40.52%
1Y Performance:
-67.07%
1-Day Range:
$2.64
$2.82
1-Week Range:
$2.28
$2.82
52-Week Range:
$1.15
$9.79
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
2.73 | 356.77M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte rises on Symvess sale to military treatment facility - MSN
Humacyte Inc. Equity Warrant Stock Analysis and ForecastRapid wealth multiplication - jammulinksnews.com
Humacyte shares climb 6% after first Symvess sale to U.S. military hospital - MSN
Is Humacyte Inc. Equity Warrant a good long term investmentUnprecedented profit potential - Autocar Professional
Humacyte stock rises after first Symvess sale to US Military facility - Investing.com India
Humacyte Announces First Symvess™ Sale to Military Treatment Facility - The Manila Times
Humacyte Breaks Into Military Healthcare: FDA-Approved Symvess Now Serving 200,000 Military Personnel - Stock Titan
What drives Humacyte Inc. stock priceFree Consultation - Autocar Professional
What analysts say about Humacyte Inc. stockMassive profits - jammulinksnews.com
Humacyte Inc. Stock Analysis and ForecastFree Advanced Stock Screener Access - jammulinksnews.com
Is Humacyte Inc. a good long term investmentOutstanding risk-reward balance - jammulinksnews.com
What analysts say about Humacyte Inc. Equity Warrant stockConsistently profitable trades - jammulinksnews.com
What drives Humacyte Inc. Equity Warrant stock priceFree Stock Selection - Autocar Professional
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know - MSN
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders - ACCESS Newswire
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026 - MSN
Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today - MSN
Lobbying Update: $10,000 of HUMACYTE lobbying was just disclosed - Nasdaq
Humacyte jumps as DoD issues ECAT listing approval for Symvess - MSN
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors - MSN
Positive week for Humacyte, Inc. (NASDAQ:HUMA) institutional investors who lost 56% over the past year - simplywall.st
Humacyte's Symvess ECAT Listing: A Strategic Catalyst for Biotech's Comeback - AInvest
Humacyte’s Symvess gains DOD electronic catalog listing approval By Investing.com - Investing.com South Africa
Humacyte's Symvess ECAT Approval: A Strategic Play for Dominance in Vascular Trauma and Beyond - AInvest
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Humacyte Inc Stock (HUMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sander Dale A. | CFO and Chief Corp. Deve. Off. |
Apr 10 '25 |
Buy |
1.53 |
20,000 |
30,600 |
40,600 |
| Parikh Shamik J | Chief Medical Officer |
Apr 10 '25 |
Buy |
1.55 |
7,500 |
11,625 |
7,500 |
| Sebelius Kathleen | Director |
Apr 08 '25 |
Buy |
1.32 |
50,000 |
66,000 |
91,207 |
| Green Charles Bruce | Director |
Apr 08 '25 |
Buy |
1.29 |
6,000 |
7,740 |
8,400 |
| Constantino Michael T. | Director |
Apr 07 '25 |
Buy |
1.26 |
16,000 |
20,160 |
32,950 |
| Constantino Michael T. | Director |
Dec 04 '24 |
Buy |
4.39 |
4,600 |
20,181 |
16,950 |
| Niklason Laura E | President, CEO and Director |
Nov 19 '24 |
Buy |
4.44 |
1,797 |
7,979 |
243,851 |
| Dougan Brady W | Director |
Nov 19 '24 |
Buy |
4.44 |
1,797 |
7,979 |
243,851 |
| Niklason Laura E | President, CEO and Director |
Nov 18 '24 |
Sale |
4.44 |
811,172 |
3,601,604 |
2,419,712 |
| Niklason Laura E | President, CEO and Director |
Nov 19 '24 |
Sale |
4.34 |
427,459 |
1,855,172 |
1,992,253 |
4.91%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):